Evidence map›Paper›PMID 34179341›Full record

ArticlePleura and peritoneum2021

Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer.

José M Porcel, Paola Murata, Laura Porcel, Silvia Bielsa, Marina Pardina, Antonieta Salud

Open access · diamondAbstract read
In one paragraph

Article in Pleura and peritoneum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

José M PorcelPleural Medicine Unit, Department of Internal Medicine, Hospital Universitari Arnau de Vilanova, IRBLleida, University of Lleida, Lleida, Spain.
Paola MurataDepartment of Medical Oncology, Hospital Universitari Arnau de Vilanova, IRBLleida, Lleida, Spain.
Laura PorcelDepartment of Internal Medicine, Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain.
Silvia BielsaPleural Medicine Unit, Department of Internal Medicine, Hospital Universitari Arnau de Vilanova, IRBLleida, University of Lleida, Lleida, Spain.
Marina PardinaDepartment of Radiology, Hospital Universitari Arnau de Vilanova, IRBLleida, Lleida, Spain.
Antonieta SaludDepartment of Medical Oncology, Hospital Universitari Arnau de Vilanova, IRBLleida, Lleida, Spain.
Universitat de Lleida · ESBiomedical Research Institute of Lleida · ESHospital Universitari Arnau de Vilanova · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe prevalence, clinical characteristics and prognosis of pleural effusions (PEs) associated with ovarian cancer (OC) have seldom been addressed systematically, as in the current investigation.

methodsAll records of consecutive women with a newly diagnosed OC in our institution over a 13-year period were retrospectively reviewed. Features of PEs on CT scans, pleural fluid analyses, need for definitive therapy of PEs, and the influence of PEs on the overall survival (OS) and progression-free survival (PFS) were evaluated.

resultsPEs were observed in 81 (43%) of 189 women with OC, either at presentation of cancer (55 patients) or during the course of the disease (26 patients). The causes of PEs were malignancy (55.5%), unknown (37%), or surgery-related (7.4%). The sensitivity of the cytologic diagnosis of malignant PEs was 79.1%. Sixty percent of malignant PEs required pleurodesis or indwelling pleural catheters for symptomatic relief. The presence of ascites strongly predicted PE development (odds ratio 43.2). Women with PEs fared much worse compared with those without PEs, in terms of OS (26.7 vs. 90.4 months), PFS (9.8 vs. 55.3 months) and tumor recurrences (86.4 vs. 43%). In multivariate analyses, PE remained as a relevant independent variable associated with poor outcome (hazard ratio 9.73 for OS, and 3.87 for PFS). Notably, PEs small enough to preclude tapping, and thus of unknown origin, had a similar bad prognosis as malignant PEs.

conclusionsOC patients with PEs experience decreased survival, including those with trace effusions not amenable to tapping.

Indexed as

indwelling pleural catheterovarian cancerpleural effusionpleurodesissurvival

Identifiers

PMID34179341
PMCPMC8216844
OpenAlexW3145393981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.